Efficacy of continuous subcutaneous insulin infusion (CSII) in patients with classical contraindications to its use [2]

Diabetic Medicine

Volumn 24, Issue 12, 2007, Pages 1496-1497

  Berkeley, J ^a   Lunt, H ^a,b   Frampton, C ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

BODY MASS; CONTINUOUS INFUSION; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG INDICATION; HUMAN; INSULIN INFUSION; LETTER; NEW ZEALAND;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; NEW ZEALAND;

EID: 36549082848     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02264.x     Document Type: Letter

References (3)

1. Rodrigues IAS, Reid HA, Ismail K, Amiel SA. Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service. Diabet Med 2005 22 : 842 849.
2. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003 26 : 1079 1087.
3. Guinn TS, Bailey GJ, Mecklenburg RS. Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care 1988 11 : 46 51.